Activated Protein C (APC) Resistance: Considerations about the Importance of Using the Original and Modified Methods in Thrombophilic Disease

Activated Protein C (APC) Resistance: Considerations about the Importance of Using the Original and Modified Methods in Thrombophilic Disease -

[1]  M. Kovacs,et al.  Inter-assay and Instrument Variability of Anti-Xa – Results , 2000, Thrombosis and Haemostasis.

[2]  S. Kitchen,et al.  Anti Xa Monitoring during Treatment with Low Molecular Weight Heparin or Danaparoid: Inter-assay Variability , 1999, Thrombosis and Haemostasis.

[3]  R. Bertina.  Molecular Risk Factors for Thrombosis , 1999, Thrombosis and Haemostasis.

[4]  B. Dahlbäck.  Activated Protein C Resistance and Thrombosis: Molecular Mechanisms of Hypercoagulable State Due to FVR506Q Mutation , 1999, Seminars in thrombosis and hemostasis.

[5]  F. Rosendaal,et al.  A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. , 1999, Blood.

[6]  W. Poewe,et al.  Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. , 1999, Circulation.

[7]  M. Kovacs,et al.  Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. , 1999, Clinical and laboratory haematology.

[8]  J. Aznar,et al.  Modified test for activated protein C resistance , 1994, The Lancet.

[9]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.